Wilm’s Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation
Sign Up to like & getrecommendations! Published in 2020 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-020-01039-2
Abstract: Hypomethylating agents (HMA) for relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic transplantation (allo-SCT) are most effective when used at the stage of molecular relapse. As Wilm’s Tumor 1 (WT1)- expression has… read more here.
Keywords: allogeneic transplantation; molecular relapse; relapse; mds allogeneic ... See more keywords
How much imatinib is enough?
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17444
Abstract: Discontinuation of imatinib treatment after a sustained deep molecular response enables a proportion of people with chronic myeloid leukaemia (CML) to achieve treatment-free remission (TFR). Other patients experience a molecular relapse with rising BCR-ABL1 levels… read more here.
Keywords: molecular relapse; treatment; relapse; trad study ... See more keywords
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
Sign Up to like & getrecommendations! Published in 2017 at "Haematologica"
DOI: 10.3324/haematol.2017.165001
Abstract: Despite persistence of leukemic stem cells, patients with chronic myeloid leukemia who achieve and maintain deep molecular responses may successfully stop the tyrosine kinase inhibitor imatinib. However, questions remain unanswered regarding the biological basis of… read more here.
Keywords: molecular relapse; natural killer; killer; killer cell ... See more keywords